Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II carboplatin + paclitaxel + bevacizumab followed by bevacizumab + erlotinib beyond progression in advanced NSCLC
NL-OMON31631Phase 2Not yet recruiting
- Sponsor
- Radboud University Medical Center
- Start
- May 2008
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin, paclitaxel, bevacizumab and erlotinib in non-small cell lung cancer (NSCLC), sponsored by Radboud University Medical Center. Primary endpoint: Maximum achieved disease control rate at 18 weeks during bevacizumab + erlotinib. Planned start May 2008; status: not yet recruiting.
02
Drugs
carboplatinpaclitaxelbevacizumaberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON31631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31631.